Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Pharmacogenomics J. 2012 Apr 10;13(4):369–377. doi: 10.1038/tpj.2012.10

TABLE 2.

CYP2C19 Genotype Frequencies

Observed (expecteda) frequency (%)
Predicted CYP2C19 metabolizer phenotype/genotype African-American (n = 250) Asian (n = 250) Caucasian (n = 250) Hispanic(n = 250) Ashkenazi Jewishb (n = 250)
Ultrarapid Metabolizer (UM)
 *17/*17 2.8 (3.3) 1.6 (0.4) 2.8 (2.5) 2.4 (2.3) 3.6 (3.9)
Extensive Metabolizer (EM)
 *1/*1 38.4 (35.3) 36.4 (37.7) 49.2 (48.4) 50.4 (49.6) 41.6 (39.9)
 *1/*17c 20.4 (21.6) 5.6 (7.6) 22.8 (22.0) 20.4 (21.4) 25.2 (25.0)

TOTAL: 58.8 (56.9) 42.0 (45.3) 72.0 (70.4) 70.8 (71.0) 66.8 (65.0)
Intermediate Metabolizer (IM)
 *1/*2 18.4 (23.0) 37.2 (33.9) 16.4 (18.4) 17.2 (18.0) 16.0 (18.5)
 *1/*3 0.4 (0.5) 7.2 (5.9) 0.4 (0.6) 0.0 (0.0) 0.0 (0.0)
 *1/*4B 0.0 (0.0) 0.0 (0.0) 0.0 (0.6) 0.0 (0.3) 2.0 (2.5)
 *1/*6 0.0 (0.0) 0.0 (0.0) 0.4 (0.3) 0.0 (0.0) 0.0 (0.0)
 *1/*8 0.0 (0.0) 0.0 (0.0) 0.4 (0.3) 0.4 (0.6) 0.0 (0.0)

TOTAL: 18.8 (23.5) 44.4 (39.8) 17.6 (20.0) 17.7 (18.9) 18.0 (21.0)
Poor Metabolizer (PM)
 *2/*2 4.8 (3.8) 6.4 (7.6) 2.8 (1.7) 2.0 (1.6) 2.8 (2.1)
 *2/*3 0.4 (0.2) 1.6 (2.6) 0.4 (0.1) 0.0 (0.0) 0.0 (0.0)
 *2/*4B 0.0 (0.0) 0.0 (0.0) 0.8 (0.1) 0.0 (0.1) 0.8 (0.6)
 *3/*3 0.0 (0.0) 0.4 (0.2) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)

TOTAL: 5.2 (3.9) 8.4 (10.5) 4.0 (2.0) 2.0 (1.8) 3.6 (2.8)
Unknown
 *1/*9 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.4 (0.3) 0.0 (0.0)
 *1/*13 0.8 (1.4) 0.0 (0.0) 0.0 (0.0) 0.8 (0.6) 0.0 (0.0)
 *1/*15 2.0 (1.7) 0.0 (0.0) 0.4 (0.3) 0.8 (0.6) 0.0 (0.0)
 *2/*13 0.8 (0.5) 0.0 (0.0) 0.0 (0.0) 0.0 (0.1) 0.0 (0.0)
 *2/*15 0.4 (0.5) 0.0 (0.0) 0.0 (0.1) 0.0 (0.1) 0.4 (0.1)
 *2/*17 9.2 (7.1) 3.6 (3.4) 3.2 (4.2) 4.4 (3.9) 6.4 (5.8)
 *3/*17 0.0 (0.1) 0.0 (0.6) 0.0 (0.1) 0.0 (0.0) 0.0 (0.0)
 *4B/*15 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.4 (0.0)
 *4B/*17 0.0 (0.0) 0.0 (0.0) 0.0(0.1) 0.4(0.1) 0.8 (0.8)
 *8/*17 0.4 (0.1) 0.0 (0.0) 0.0 (0.1) 0.4 (0.1) 0.0 (0.0)
 *13/*17 0.8 (0.4) 0.0 (0.0) 0.0 (0.0) 0.0 (0.1) 0.0 (0.0)
 *15/*17 0.4 (0.5) 0.0 (0.0) 0.0 (0.1) 0.0 (0.1) 0.0 (0.2)

TOTAL: 14.4 (12.3) 3.6 (4.0) 3.6 (4.9) 7.2 (5.9) 8.0 (7.4)

n: number of subjects.

a

Predicted Hardy-Weinberg frequencies.

b

Data from Scott et al., 2011.26

c

Although some studies classify *1/*17 individuals as ultrarapid metabolizers, the extensive metabolizer classification is consistent with Li-Wan-Po, et al., 2010.68